References

REFERENCES
1). American Cancer Society Cervical Cancer Copyright, www.cancer.org, 2012. 2). Andersson S, Alemi M, Rylander E, Strand A,Larsson B, Sallstrom J, and Wilander E, Uneven distribution of HPV 16 E6 prototype and variant (L83V) oncoprotein in cervical neoplastic lesions, Br. J. Cancer 83:307310, 2004. 3). Baay M F D , Koudstaal J, Hollema H, Duk J M, Burger M P M, Quint W G V, Stolz E, Herbrink P, Detection of HPV-1 6 DNA by PCR in Histologically cancer free lymph nodes from Patients with cervical cancer,p. 92, Journal of Virology, 1997. 4). Baker CC, Phelps WC, Lindgren V, Braun J, Gonda M, and Howley PM, Structural and Transcriptional Analysis of Human Papillomavirus Type 16 Sequences in Cervical Carcinoma Cell Lines ,Journal of Virology, p. 962-971. Apr, 1987 5). Baldwin A, Edwards KM, Hayakawa H, Nguyen CL, Owens M, Grace M, and Huh KW, Minireview - Mechanisms of Human Papillomavirus-Induced Oncogenesis Journal of Virology, p. 1145111460, Nov, 2004. 6). Bernard HU, Chan SY, Manos MM, Ong CK, Villa LL, Deliu H, Peyton CL, Bauer HM, and Wheeler CM, Identification and assessment of known and novel human papillomaviruses by polymerase chain reaction amplification, restriction fragment length polymorphisms, nucleotide sequence, and phylogenetic algorithms, J. Infect. Dis. 170:1077 1085, 1994. 7). Burd EM, Human Papillomavirus and Cervical Cancer,Clinical microbiology reviews, Jan. p. 117, 2003. 8). Carroll a R, Coleman R L, and Sood a K, Therapeutic advances in womens cancers, BioMed Central, Oct, 2011. 9). Das B C, Sharma J K, Gopalakrishna V, and Luthra U K, Analysis by polymerase chain reaction of the physical state of human papillomavirus type 16 DNA in cervical preneoplastic and neoplastic lesions, J.Gen. Virol. 73:23272336, 1992. 10). Das B C, Sharma J K, Gopalkrishna V, Das D K, Singh V, Gissmann L, Hausen H Z, and Luthra U K, A high frequency of human papillomavirus DNA sequences in cervical carcinomas of Indian women as revealed by Southern blot hybridization and polymerase chain reaction, J. Med. Virol. 36: 239245, 1992. 11).Duarte V M, Han E, Veena M S, Salvado A, Suh J D, Liang L J, Faull K F, Srivatsan E S, and Wang M B Curcumin enhances the effect of cisplatin in suppression of head and neck squamous cell carcinoma via inhibition of IKK protein of the nuclear factor kB pathway, Mol Cancer Ther. October; 9(10): 26652675, 2010. 12). Galea A M and Murray V, The Anti-tumour Agent, Cisplatin, and its Clinically Ineffective Isomer, Transplatin, Produce Unique Gene Expression Profiles in Human Cells, Cancer Informatics: 6 315355, 2008.
Department Of Pharmaceutical Sciences, Kumaun University Page 11

References 13). Gonzlez A D,Lizano M, Candelaria M, Cetina L, Arce C and Cervera E, Epigenetics of cervical cancer. An overview and therapeutic Perspectives, BioMed Central, 2005. 14). Gonzlez A D, Lpez P G, Herrera L A, Franco J L M, Fierro A G and Candelaria M, The prince and the pauper. A tale of anticancer targeted agents, BioMed Central, Oct, 2008. 15). Hausen H Z, Papillomaviruses and cancer: from basic studies to clinical application. Nat. Rev. Cancer, 2:34235, 2002. 16). HO L, CHAN S Y,' The Genetic Drift of Human Papillomavirus Type 16 Is a Means of Reconstructing Prehistoric Viral Spread and the Movement of Ancient Human Populations,Journal of Virology, Nov., p. 6413-6423, 1993. 17).Kozuka T, Aoki Y, Nakagawa K, Ohtomo K, Yoshikawa H, Matsumoto K, Yoshiike K and Kanda T, Enhancer-promoter Activity of Human Papillomavirus Type 16 Long Control Regions Isolated from Cell Lines SiHa and CaSki and Cervical Cancer Biopsies. Jpn. J. Cancer Res. 91, 271279, March, 2000. 18). Lace M J, Isacson C, Anson J R, Lorincz A T, Wilczynski S P, Haugen T H, and Turek L P, Upstream Regulatory Region Alterations Found in Human Papillomavirus Type 16 (HPV-16) Isolates from Cervical Carcinomas Increase Transcription, ori Function, and HPV Immortalization Capacity in Culture, Journal of Virology, Aug. p. 74577466, 2009. 19). Mahata S, Bharti A C, Shukla S, Tyagi A, Husain2 S A and Das B C,Berberine modulates AP-1 activity to suppress HPV, Transcription and downstream signalling to induce Growth arrest and apoptosis in cervical cancer cells, Molecular cancer, 2011. 20). Mayrand M H, Coutlee F, Hankins C, Lapointe N, Forest P, Ladurantaye M D, Detection of Human Papillomavirus Type 16 DNA in Consecutive Genital Samples Does Not Always Represent Persistent Infection as Determined by Molecular Variant Analysis. Journal Of Clinical Microbiology, Sept. p. 33883393, 2002. 21). Meissner J D, Nucleotide sequences and further characterization of human Papillomavirus DNA present in the CaSki, SiHa and HeLa Cervical carcinoma cell lines, Journal of General Virology ,80, 17251733, 1999. 22). OConnor M, Chan S Y, and Bernard H U, Transcription Factor Binding Sites in the Long Control Region of Genital HPV, Pub. Med. Central, 1995. 23). Pande S, Jain N, Prusty B K, Bhambhani S, Gupta S, Sharma R, Batra S, and Das B C, Human Papillomavirus Type 16 Variant Analysis of E6, E7, and L1 Genes and Long Control Region in Biopsy Samples from Cervical Cancer Patients in North India Journal of Clinical Microbiology, Mar, 2008. 24). Royal College of Nursing, HPV and Cervical cancer- the facts, Rcnonline, 2006. 25). Satija A, Sankaranarayanan and Wesley R S, Cervical Cancer In India, South Asia Centre for Chronic Disease, 2003.
Department Of Pharmaceutical Sciences, Kumaun University Page 12

References

26). Shang Q, Wang Y, Fang Y, Wei L, Chen S, Sun Y, Li B, Zhang F,and Gu H Human Papillomavirus Type 16 Variant Analysis of E6, E7, and L1 Genes and Long Control Region in Identification of Cervical Carcinomas in Patients in Northeast China. Journal of Clinical Microbiology, July, p. 26562663, 2011. 27). Shin Kuo et.al Paclitaxel plus Oxaliplatin for Recurrent or Metastatic Cervical Cancer: A New York Cancer Consortium Study, Gynecol Oncol. March; 116(3): 442, 2010. 28). Sol E S, Lee T S, Koh S B, Oh H K, Ye G W, Choi Y S, Comparison of concurrent chemoradiotherapy with cisplatin plus 5-fluorouracil versus cisplatin plus paclitaxel in patients with locally advanced cervical carcinoma, J Gynecol Oncol Vol. 20, No. 1:28-34, March, 2009. 29). Yamada T, Wheeler C M, Halpern A L, Stewart A M, Hildesheim A, and Jenison S A,Human Papillomavirus Type 16 Variant Lineages in United States Populations Characterized by Nucleotide Sequence Analysis of the E6, L2, and L1 Coding Segments. Journal of Virology, Dec, p. 7743-7753, 1995. 30). Zehbe I, Lichtig H, Westerback A, Lambert P F, Tommasino M and Sherman L, Rare human papillomavirus 16 E6 variants reveal significant oncogenic potential, Molecular Cancer, 2011. 31). Zheng Z M and Baker C C, Papillomavirus genome structure, expression, and posttranscriptional regulation, Pub. Med. Central, 2006.

Department Of Pharmaceutical Sciences, Kumaun University

Page 13